E

An alternative perspective on TIGIT

What can we learn from IO trials in lung cancer to help us evaluate TIGIT's prospects?

June 23, 2022
E

Seeing the wood from the trees in early stage oncology pipelines

Exploring future IO-IO combination strategies and life cycle management

June 16, 2022
E

A critical review of five different targeted therapy approaches at ASCO

Where five different targeted therapies are put through their paces

June 13, 2022
E

The good, the bad, the plain old ugly, and the promising

There’s always a parable or two to be had at ASCO and this year was no different, especially in…

June 7, 2022
E

Talkin’ ’bout a Revolution

The continuous evolution of BCMA CAR-T cell therapy products and how they are doing

June 6, 2022
E

Trials and Tribulations

A look at early stage CAR-T cell therapies in development

June 5, 2022
E

ASCO22 Highlights from Day 1

When cell therapies and targeted therapies collide

June 4, 2022
E

Five key areas to watch out for at ASCO22

Five key areas to watch out for at ASCO22

June 1, 2022
E

The Forgotten Checkpoints

What can we learn from the data on inhibitory checkpoints not named PD(L)1 or TIGIT?

May 26, 2022
E

A high level view of the latest Target Protein Degradation data

What's the skinny on C4 Therapeutics and other TPD programs at AACR and ASCO?

May 16, 2022
E

Take the high road

5 abstracts to watch out for at the ASCO22 meeting in Chicago

May 2, 2022
E

A journey that never ends

Can NK cells help checkpoint blockade work more effectively?

April 27, 2022